Global Multiple Hereditary Exostosis Market Segmentation, By Type (Sessile and Pedunculated), Treatment (Surgery, Medication, and Others), Diagnosis (X-ray, Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Genetic Tests, and Others), Site (Legs, Arms, Shoulders, Pelvis, Fingers, and Toes), Age Group (Pediatric and Adult), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others) - Industry Trends and Forecast to 2031
Multiple Hereditary Exostosis Market Analysis
MHE is a rare genetic disorder characterized by multiple benign bone tumors (osteochondromas), leading to deformities, pain, and restricted mobility in severe cases. Growing awareness of MHE and hereditary conditions is expected to act as a driver for market growth. Although, advanced therapies like palovarotene are associated with significant annual costs, rendering effective treatment inaccessible for many patients, especially those lacking sufficient insurance coverage. This is expected to act as a restraint on market growth.
Multiple Hereditary Exostosis Market Size
Global multiple hereditary exostosis market size was valued at USD 121.25 million in 2023 and is projected to reach USD 161.89 million by 2031, with a CAGR of 3.7% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Multiple Hereditary Exostosis Market Trends
“Increasing Awareness and Advancements in Genetic Research”
The global Multiple Hereditary Exostosis (MHE) market is witnessing a significant trend towards increasing awareness and advancements in genetic research related to the condition. As healthcare professionals and patients become more informed about MHE, there is a growing demand for accurate diagnosis and effective treatment options. Scientific developments in genetic testing and molecular biology are enhancing the understanding of the underlying mechanisms of MHE, leading to personalized medicine approaches. Moreover, enhanced educational initiatives and patient advocacy efforts are contributing to the proliferation of knowledge regarding MHE, thus encouraging more individuals to seek medical advice. This shift not only drives the demand for specialized healthcare services but also fuels the growth of the pharmaceutical sector, with companies exploring innovative therapies and interventions aimed at managing MHE more effectively. Overall, the convergence of awareness, education, and research is poised to shape the landscape of the MHE market significantly in the coming years.
Report Scope and Multiple Hereditary Exostosis Market Segmentation
|
Attributes
|
Multiple Hereditary Exostosis Market Insights
|
|
Segments Covered
|
|
|
Countries Covered
|
U.S., Canada, and Mexico, Germany, U.K., France, Italy, Spain, Russia, Turkey, Switzerland, Belgium, Netherland, Denmark, Sweden, Poland, Norway, Finland, and Rest of Europe, Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Taiwan, Vietnam, New Zealand, Australia, and Rest of Asia-Pacific, Brazil, Argentina, and Rest of South America, South Africa, Egypt, Saudi Arabia, Kuwait, Qatar, Oman, Bahrain, U.A.E., and Rest of Middle East and Africa
|
|
Key Market Players
|
Bayer AG (Germany), Haleon Group of Companies (UK), BASF (Germany), Viatris Inc. (U.S.), Mallinckrodt (U.S.), AdvaCare Pharma (U.S.), Aurobindo Pharma (India), Taj Pharmaceutical Limited (India), Wellona Pharma (India), and ActizaPharma (India) among others
|
|
Market Opportunities
|
|
|
Value Added Data Infosets
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Multiple Hereditary Exostosis Market Definition
Multiple Hereditary Exostosis (MHE), also known as Hereditary Multiple Exostoses (HME), is a genetic disorder characterized by the development of multiple benign bone tumors called exostoses or osteochondromas. These typically arise from the growth of cartilage at the ends of long bones and can occur at various sites throughout the body. MHE is usually inherited in an autosomal dominant pattern; meaning only one copy of the mutated gene is needed for the condition to manifest. Individuals with MHE may experience pain, complications from the exostoses such as deformities or restricted motion, and an increased risk of developing osteosarcoma, a type of bone cancer.
Multiple Hereditary Exostosis Market Dynamics
Drivers
- Rising Prevalence of Genetic Disorders
MHE is a rare genetic disorder characterized by the development of multiple benign bone tumors (osteochondromas) that can lead to physical deformities, pain, and, in severe cases, restricted mobility. As awareness about MHE and other hereditary conditions increases, the need for effective diagnosis and therapeutic interventions has surged.
For instance,
- In December 2019, according to an article published by National Institutes of Health, the prevalence of HME (Hereditary Multiple Exostoses) in Western populations is estimated to range between 0.4 to 1 per 50,000 individuals. However, among the Chamorro people of Guam, the prevalence is significantly higher, reaching 50 per 50,000. In Western countries, the incidence of this condition is reported to increase by 1.5% annually. This rising prevalence of genetic disorders, such as HME, highlights the growing need for effective treatments, which will drive the global multiple hereditary exostosis market as healthcare systems prioritize diagnosis and management of such conditions.
With advancements in genetic screening and diagnostics, early detection of MHE is becoming more feasible, which allows for timely intervention and improved patient outcomes. Genetic testing has become a vital tool in identifying carriers and at-risk individuals, enabling personalized treatment plans and targeted therapies. The demand for such diagnostic technologies is growing as more healthcare providers recognize the importance of early diagnosis in managing genetic disorders like MHE.
- Growing Pediatric Population
Multiple Hereditary Exostosis (MHE) predominantly affects children, typically presenting symptoms during early childhood or adolescence. As the global pediatric population grows, there is an increased likelihood of more cases being diagnosed, which directly fuels the demand for early diagnosis and effective treatment options. MHE can cause bone deformities, restricted movement, and complications that significantly impact a child's growth and quality of life, making timely intervention essential.
For instance,
- In May 2023, according to an article published by ScienceDirect, India's expanding pediatric population, coupled with increasing affordability, emphasizes the urgent need for improved healthcare services. Although children aged 0 to 18 make up 39% of the population, the highest percentage globally, healthcare infrastructure remains a critical focus. The substantial pediatric demographic in India highlights the need for specialized healthcare solutions, driving the global multiple hereditary exostosis market as demand for pediatric genetic disorder diagnosis and treatment rises in this large and growing population.
The expanding pediatric population, particularly in developing regions, has led to a higher focus on pediatric healthcare infrastructure. Governments and healthcare organizations are recognizing the need to strengthen genetic screening programs and offer specialized pediatric care. As more children are diagnosed with MHE, the demand for genetic testing, regular monitoring, and surgical interventions to manage the disorder is rising. This creates a steady need for advanced diagnostic tools and therapeutic options tailored specifically for children.
Opportunities
- Increase in Patient Care and Support Systems
The increase in patient care and support systems is significantly transforming the global multiple hereditary exostosis market. As healthcare systems worldwide emphasize patient-centered care, the demand for tailored treatments and comprehensive support has surged. This trend is particularly relevant for MHE, a genetic disorder characterized by the formation of multiple benign bone growths.
With advancements in technology and the rise of telemedicine, patient support systems are becoming more accessible and efficient. Digital platforms allow patients to connect with healthcare professionals, share experiences, and access valuable resources. These developments enable better management of MHE symptoms and promote early intervention, which can mitigate complications. As patients become more informed and empowered, the demand for innovative therapies and management options is likely to increase, creating opportunities for pharmaceutical and biotech companies to expand their product offerings in the MHE market.
- Increase in the Number of Collaborations and Partnerships
The surge in partnerships and collaborations between pharmaceutical companies, research institutions, and medical device manufacturers presents a significant opportunity for the global multiple hereditary exostosis market. These partnerships can expedite the development of novel treatments and therapies by fostering knowledge sharing, expertise exchange, and resource pooling, in turn addressing the unmet needs of MHE patients.
Companies can combine existing technologies and therapies to create innovative solutions through strategic partnerships. The increase in partnerships and collaborations is likely to drive investment in MHE research, which will, in turn, fuel innovation and growth in the market. As pharmaceutical companies and medical device manufacturers collaborate with other organizations to address the needs of MHE patients, it is expected to witness increased investment in research and development, leading to a greater understanding of the underlying causes of MHE and the development of more effective treatments.
Restraints/Challenges
- High Cost of Advanced Therapies
The "high cost of advanced therapies" poses a significant restraint on the global Multiple Hereditary Exostosis (MHE) market due to its multifaceted impact on treatment accessibility and healthcare systems. Advanced therapies, such as palovarotene, come with substantial annual costs making effective treatment unattainable for many, particularly those without adequate insurance coverage. The reliance on costly diagnostic tools like MRI and CT scans, as outlined in the "Diagnosis" section, adds to the financial burden, deterring timely treatment and potentially leading to worse health outcomes.
For instance,
- In August 2023, according to an article published by NCBI, the annual cost of palovarotene is estimated to be around USD 622,373 for patients between the ages of 8 and 14, and USD 1,022,894 for those aged 14 and older. This high cost of advanced therapies serves as a major restraint for the global multiple hereditary exostosis market, as the substantial financial burden limits access to treatment, particularly for patients without sufficient insurance coverage or in regions with constrained healthcare funding.
Limited Availability of Therapies
The limited availability of effective therapies remains a significant restraint on the growth of the global multiple hereditary exostosis market. Despite advancements in research and the promise shown by emerging drugs like palovarotene, the current therapeutic landscape for MHE is still underdeveloped. Palovarotene, while a promising treatment, is not yet widely available or approved in all regions, limiting its accessibility to a broader patient population.
Moreover, there are very few medications specifically designed to target the underlying causes of MHE. Most available treatments are focused on managing the symptoms, such as pain relief through medications like ibuprofen or surgical interventions to remove osteochondromas. However, these treatments do not address the genetic basis of the disease, leaving patients with limited options for long-term, disease-modifying therapies.
For instance,
- In December 2019, according to an article published by National Institutes of Health, resection, limb shortening, and surgical deformity correction are the only treatment options currently available, primarily recommended in symptomatic cases or when there is suspicion of malignant transformation.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Multiple Hereditary Exostosis Market Scope
The market is segmented based on type, treatment, diagnosis, site, age group, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Sessile
- Pedunculated
Treatment
- Surgery
- Remove The Tumor
- Lengthen Limbs
- Medication
- Hospital Pharmacies
- Drugs Stores and Retail Pharmacies
- Online Pharmacies
- Others
Diagnosis
- X-Ray
- Sessile
- Pedunculated
- Computed Tomography (CT) Scan
- Sessile
- Pedunculated
- Magnetic Resonance Imaging (MRI)
- Sessile
- Pedunculated
- Genetic Tests
- Sessile
- Pedunculated
- Others
- Sessile
- Pedunculated
Site
- Legs
- Arms
- Shoulders
- Pelvis
- Fingers
- Toes
Age Group
- Pediatric
- Adult
End User
- Hospitals
- Private
- Government
- Specialty Clinics
- Ambulatory Surgical Centers
- Others
Multiple Hereditary Exostosis Market Regional Analysis
The market is analyzed and market size insights and trends are provided by country, type, treatment, diagnosis, site, age group, end user as referenced above.
The countries covered in the market are U.S., Canada, and Mexico, Germany, U.K., France, Italy, Spain, Russia, Turkey, Switzerland, Belgium, Netherland, Denmark, Sweden, Poland, Norway, Finland, and rest of Europe, Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Taiwan, Vietnam, New Zealand, Australia, and rest of Asia-Pacific, Brazil, Argentina, and rest of South America, South Africa, Egypt, Saudi Arabia, Kuwait, Qatar, Oman, Bahrain, U.A.E., and rest of Middle East and Africa.
North America is expected to dominate the market due to advanced healthcare infrastructure, high awareness levels, and robust research funding for genetic disorders. Additionally, the presence of key pharmaceutical companies and innovative treatment options further drive market growth in the region.
Asia-Pacific is expected to be the fastest growing region due to increasing population awareness, rising healthcare expenditures, and a growing emphasis on genetic research and treatments. Additionally, improving access to advanced medical technologies and therapies in emerging economies contributes to the market's rapid expansion.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Multiple Hereditary Exostosis Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Global Multiple Hereditary Exostosis Market Leaders Operating in the Market Are:
- Bayer AG (Germany)
- Haleon Group of Companies (UK)
- BASF (Germany)
- Viatris Inc. (U.S.)
- Mallinckrodt (U.S.)
- AdvaCare Pharma (U.S.)
- Aurobindo Pharma (India)
- Taj Pharmaceutical Limited (India)
- Wellona Pharma (India)
- ActizaPharma (India)
- Lqms Software Solutions (USA)
- Starlims Corporation (A Subsidiary Of Abbott) (USA)
Latest Developments in Global Multiple Hereditary Exostosis Market
- In January 2023, Ipsen entered into acquisition of Albireo, enhancing its rare disease portfolio with Bylvay (odevixibat), the first approved treatment for progressive familial intrahepatic cholestasis. This strategic move aims to accelerate growth in rare pediatric liver diseases, bolstering Ipsen’s market presence and expanding treatment options for underserved patients.
SKU-